Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03338244 · ClinicalTrials.gov registry record · Phase 4
Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 66,228
- Enrollment target
NCT03338244: Completed Phase 4 study, sponsored by University of California, San Francisco.
NCT03338244 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 66,228 participants, above the 511-participant average among 9,235 other Phase 4 trials with a reported enrollment target (12860% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03338244, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66,228 participants
- Enrollment target
Study Summary
MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality. All communities were subsequently treated with mass azithromycin for one year. The present trial re-randomized communities to azithromycin or placebo for the fourth and fifth year of the study.
Primary Outcome
as measured by presence on census and absence on sequential census due to death
Interventions
- DRUG Placebo
- DRUG Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66,228 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 4 |
What the finished NCT03338244 record still lists
NCT03338244 is an interventional study that assigns participants to a tested intervention. Its 66,228 participants enrollment target places it among the larger protocols in the corpus, above the 511-participant average among 9,235 other Phase 4 trials with a reported enrollment target (12860% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03338244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03338244 about?
NCT03338244 is a clinical study titled "Mortality Reduction After Oral Azithromycin Contingency: Mortality Study". MORDOR was a cluster-randomized placebo controlled trial that assessed the efficacy of mass azithromycin distributions for the prevention of childhood mortality. All communities were subsequently treated with mass azithromycin for one year. The present trial re-randomized communities to azithromycin...
What is the current status of trial NCT03338244?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66,228 participants. The study started on 2017-10-20. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03338244?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT03338244?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03338244's enrollment target sits among peer trials
66,228 4th of 2000 higher than 1,997 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04473833 · 65,000 participants · NA
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
- NCT00009633 · 68,000 participants
Follow-up Visit of High Risk Infants
- NCT06903897 · 68,000 participants · NA
Social Needs Screening and Chronic Diseases Study (WE CARE)
- NCT05128006 · 63,200 participants
Direct-to-patient Teledermatology and Computer-assisted Diagnosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI